Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase III study comparing 177Lu-PSMA-617 vs. change of androgen receptor-therapy in prostate pts

A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naīve Men with Progressive Metastatic Castrate Resistant Prostate Cancer

Disease Types: Prostate

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naīve Men with Progressive Metastatic Castrate Resistant Prostate Cancer

For more information:

https://clinicaltrials.gov/ct2/show/NCT04689828?cond=Lu-PSMA-617&draw=2&rank=4